Novo NordiskNovo Nordisk is putting down up to US$362m to tap into Ascendis’ TransCon technology for treatments in metabolic and cardiovascular diseases. The pharma powerhouse has its sights set on developing a once-monthly GLP-1 receptor agonist.
Tag Archive for: diabetes
In the race for global market share of its obesity and diabetes blockbuster semaglutide, Novo Nordisk is expanding production in Europe.
Stock markets love investment concepts, calling the robust ones ‘megatrends’. Golden ageing is one such megatrend banking on the fact that business can extract more from people living longer. Such megatrend investments help – up to the moment when rising interest rates crash the party.
French pancreatic beta-cell modulator specialist DiogenX SA has raised €27.5m in a Series A financing led by Boehringer Ingelheim Venture Fund and Roche Venture Fund.